{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:01:18Z","timestamp":1793689278594,"version":"4.5.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T00:00:00Z","timestamp":1555545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T00:00:00Z","timestamp":1555545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Compounds that are candidates for drug repurposing can be ranked by leveraging knowledge available in the biomedical literature and databases. This knowledge, spread across a variety of sources, can be integrated within a knowledge graph, which thereby comprehensively describes known relationships between biomedical concepts, such as drugs, diseases, genes, etc. Our work uses the semantic information between drug and disease concepts as features, which are extracted from an existing knowledge graph that integrates 200 different biological knowledge sources. RepoDB, a standard drug repurposing database which describes drug-disease combinations that were approved or that failed in clinical trials, is used to train a random forest classifier. The 10-times repeated 10-fold cross-validation performance of the classifier achieves a mean area under the receiver operating characteristic curve (AUC) of 92.2%. We apply the classifier to prioritize 21 preclinical drug repurposing candidates that have been suggested for Autosomal Dominant Polycystic Kidney Disease (ADPKD). Mozavaptan, a vasopressin V2 receptor antagonist is predicted to be the drug most likely to be approved after a clinical trial, and belongs to the same drug class as tolvaptan, the only treatment for ADPKD that is currently approved. We conclude that semantic properties of concepts in a knowledge graph can be exploited to prioritize drug repurposing candidates for testing in clinical trials.<\/jats:p>","DOI":"10.1038\/s41598-019-42806-6","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T10:08:13Z","timestamp":1555582093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Drug prioritization using the semantic properties of a knowledge graph"],"prefix":"10.1038","volume":"9","author":[{"given":"Tareq B.","family":"Malas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1096-8563","authenticated-orcid":false,"given":"Wytze J.","family":"Vlietstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Kudrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Starikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Charrout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-772X","authenticated-orcid":false,"given":"Marco","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien J. M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Kors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rein","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A. C.","family":"\u2018t Hoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1377-9386","authenticated-orcid":false,"given":"Erik M.","family":"van Mulligen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-7560","authenticated-orcid":false,"given":"Kristina M.","family":"Hettne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,18]]},"reference":[{"key":"42806_CR1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.7150\/ijbs.9224","volume":"10","author":"JS Shim","year":"2014","unstructured":"Shim, J. S. & Liu, J. O. Recent advances in drug repositioning for the discovery of new anticancer drugs. International Journal of Biological Sciences 10, 654\u2013663 (2014).","journal-title":"International Journal of Biological Sciences"},{"key":"42806_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0169-2607(98)00033-9","volume":"57","author":"NR Smalheiser","year":"1998","unstructured":"Smalheiser, N. R. & Swanson, D. R. Using ARROWSMITH: A computer-assisted approach to formulating and assessing scientific hypotheses. Comput. Methods Programs Biomed. 57, 149\u2013153 (1998).","journal-title":"Comput. Methods Programs Biomed."},{"key":"42806_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1353\/pbm.1986.0087","volume":"30","author":"DR Swanson","year":"1986","unstructured":"Swanson, D. R. Fish oil, Raynaud\u2019s syndrome, and undiscovered public knowledge. Perspect. Biol. Med. 30, 7\u201318 (1986).","journal-title":"Perspect. Biol. Med."},{"key":"42806_CR4","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.joi.2015.06.001","volume":"9","author":"KZ Vardakas","year":"2015","unstructured":"Vardakas, K. Z., Tsopanakis, G., Poulopoulou, A. & Falagas, M. E. An analysis of factors contributing to PubMed\u2019s growth. J. Informetr. 9, 592\u2013617 (2015).","journal-title":"J. Informetr."},{"key":"42806_CR5","doi-asserted-by":"publisher","first-page":"D20","DOI":"10.1093\/nar\/gkv1352","volume":"44","author":"CE Cook","year":"2016","unstructured":"Cook, C. E. et al. The European Bioinformatics Institute in 2016: Data growth and integration. Nucleic Acids Res. 44, D20\u20136 (2016).","journal-title":"Nucleic Acids Res."},{"key":"42806_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0149621","volume":"11","author":"KM Hettne","year":"2016","unstructured":"Hettne, K. M. et al. The implicitome: A resource for rationalizing gene-disease associations. PLoS One 11, 1\u201321 (2016).","journal-title":"PLoS One"},{"key":"42806_CR7","doi-asserted-by":"publisher","first-page":"96ra77","DOI":"10.1126\/scitranslmed.3001318","volume":"3","author":"M Sirota","year":"2011","unstructured":"Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011).","journal-title":"Sci. Transl. Med."},{"key":"42806_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-6-80","volume":"6","author":"H Lee","year":"2012","unstructured":"Lee, H. et al. Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug. BMC Syst. Biol. 6, 80 (2012).","journal-title":"BMC Syst. Biol."},{"key":"42806_CR9","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1039\/c2ib00154c","volume":"4","author":"S Daminelli","year":"2012","unstructured":"Daminelli, S., Haupt, V. J., Reimann, M. & Schroeder, M. Drug repositioning through incomplete bi-cliques in an integrated drug-target-disease network. Integr. Biol. (Camb). 4, 778\u201388 (2012).","journal-title":"Integr. Biol. (Camb)."},{"key":"42806_CR10","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1093\/bioinformatics\/btu403","volume":"30","author":"W Wang","year":"2014","unstructured":"Wang, W., Yang, S., Zhang, X. & Li, J. Drug repositioning by integrating target information through a heterogeneous network model. Bioinformatics 30, 2923\u20132930 (2014).","journal-title":"Bioinformatics"},{"key":"42806_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10331","volume":"7","author":"E Guney","year":"2016","unstructured":"Guney, E., Menche, J., Vidal, M. & Bar\u00e1basi, A. L. Network-based in silico drug efficacy screening. Nat. Commun. 7, 10331 (2016).","journal-title":"Nat. Commun."},{"key":"42806_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.26726","volume":"6","author":"DS Himmelstein","year":"2017","unstructured":"Himmelstein, D. S. et al. Systematic integration of biomedical knowledge prioritizes drugs for repurposing. Elife 6, 1\u201335 (2017).","journal-title":"Elife"},{"issue":"17","key":"42806_CR13","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1093\/bioinformatics\/btx275","volume":"33","author":"Mona Alshahrani","year":"2017","unstructured":"Alshahrani, M. et al. Neuro-symbolic representation learning on biological knowledge graphs. Bioinformatics 1\u20138, https:\/\/doi.org\/10.1093\/bioinformatics\/btx275 (2017).","journal-title":"Bioinformatics"},{"key":"42806_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/srep32530","volume":"6","author":"L Yu","year":"2016","unstructured":"Yu, L., Ma, X., Zhang, L., Zhang, J. & Gao, L. Prediction of new drug indications based on clinical data and network modularity. Sci. Rep. 6, 32530 (2016).","journal-title":"Sci. Rep."},{"key":"42806_CR15","first-page":"132","volume":"22","author":"E Guney","year":"2016","unstructured":"Guney, E. Reproducible drug repurposing: When similarity does not suffice. Pacific Symp. Biocomput. 22, 132\u2013143 (2016).","journal-title":"Pacific Symp. Biocomput."},{"key":"42806_CR16","first-page":"216","volume":"84","author":"AT McCray","year":"2001","unstructured":"McCray, A. T., Burgun, A. & Bodenreider, O. Aggregating UMLS semantic types for reducing conceptual complexity. Stud. Health Technol. Inform. 84, 216\u201320 (2001).","journal-title":"Stud. Health Technol. Inform."},{"key":"42806_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.29","volume":"4","author":"AS Brown","year":"2017","unstructured":"Brown, A. S. & Patel, C. J. A standard database for drug repositioning. Sci. Data 4, 170029 (2017).","journal-title":"Sci. Data"},{"key":"42806_CR18","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407\u201318 (2012).","journal-title":"N. Engl. J. Med."},{"key":"42806_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1365-2796.2006.01743.x","volume":"261","author":"VE Torres","year":"2007","unstructured":"Torres, V. E. & Harris, P. C. Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J. Intern. Med. 261, 17\u201331 (2007).","journal-title":"J. Intern. Med."},{"key":"42806_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2174\/1573402111309010008","volume":"9","author":"MV Irazabal","year":"2013","unstructured":"Irazabal, M. V. & Torres, V. E. Experimental therapies and ongoing clinical trials to slow down progression of ADPKD. Curr. Hypertens. Rev. 9, 44\u201359 (2013).","journal-title":"Curr. Hypertens. Rev."},{"key":"42806_CR21","doi-asserted-by":"crossref","unstructured":"Chang, M.-Y. & Ong, A. C. M. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron. Clin. Pract. 120, c25\u201334; discussion c35 (2012).","DOI":"10.1159\/000334166"},{"key":"42806_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1517\/13543781003588491","volume":"19","author":"FA Belibi","year":"2010","unstructured":"Belibi, F. A. & Edelstein, C. L. Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opin. Investig. Drugs 19, 315\u201328 (2010).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"42806_CR23","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00018-012-1052-z","volume":"70","author":"J Pan","year":"2013","unstructured":"Pan, J., Seeger-Nukpezah, T. & Golemis, E. A. The role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies. Cell. Mol. Life Sci. 70, 1849\u20131874 (2013).","journal-title":"Cell. Mol. Life Sci."},{"key":"42806_CR24","doi-asserted-by":"crossref","unstructured":"Stayner, C., Brooke, D. G., Bates, M. & Eccles, M. R. Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease. Curr. Med. Chem. 25 (2018).","DOI":"10.2174\/0929867325666180508095654"},{"key":"42806_CR25","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1681\/ASN.2007070771","volume":"19","author":"F Park","year":"2008","unstructured":"Park, F., Sweeney, W. E., Jia, G., Roman, R. J. & Avner, E. D. 20-HETE mediates proliferation of renal epithelial cells in polycystic kidney disease. J. Am. Soc. Nephrol. 19, 1929\u201339 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"42806_CR26","doi-asserted-by":"publisher","first-page":"F944","DOI":"10.1152\/ajprenal.00387.2010","volume":"299","author":"T Yamaguchi","year":"2010","unstructured":"Yamaguchi, T., Reif, G. A., Calvet, J. P. & Wallace, D. P. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am. J. Physiol. Renal Physiol. 299, F944\u201351 (2010).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"42806_CR27","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2215\/CJN.09900915","volume":"11","author":"P Ruggenenti","year":"2016","unstructured":"Ruggenenti, P. et al. Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. Clin. J. Am. Soc. Nephrol. 11, 785\u201394 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"42806_CR28","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1097\/HJH.0b013e32832cc56c","volume":"27","author":"Y Zhang","year":"2009","unstructured":"Zhang, Y. et al. The role of 20-hydroxyeicosatetraenoic acid in adrenocorticotrophic hormone and dexamethasone-induced hypertension. J. Hypertens. 27, 1609\u20131616 (2009).","journal-title":"J. Hypertens."},{"key":"42806_CR29","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1111\/bph.12079","volume":"168","author":"P Toth","year":"2013","unstructured":"Toth, P. et al. Treatment with the cytochrome P450 \u03c9-hydroxylase inhibitor HET0016 attenuates cerebrovascular inflammation, oxidative stress and improves vasomotor function in spontaneously hypertensive rats. Br. J. Pharmacol. 168, 1878\u20131888 (2013).","journal-title":"Br. J. Pharmacol."},{"key":"42806_CR30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/978-3-319-11964-9_7","volume":"8796","author":"C Batchelor","year":"2014","unstructured":"Batchelor, C. et al. Scientific Lenses to Support Multiple Views over Linked Chemistry Data. Semant. Web \u2013 ISWC 2014 8796, 98\u2013113 (2014).","journal-title":"Semant. Web \u2013 ISWC 2014"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42806-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42806-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42806-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:49:42Z","timestamp":1671266982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42806-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,18]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["42806"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-42806-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,18]]},"assertion":[{"value":"26 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kristina M. Hettne performed paid consultancy between November 1, 2015 and March 31, 2018 for Euretos B.V, a startup founded in 2012 that develops knowledge management and discovery services for the life sciences, with the Euretos Knowledge Platform as a marketed product.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6281"}}